Author

A. S. Mansfield

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. C. Roden· 1 shared A. Desai· 1 shared A. Feven· 1 shared A. M. Abdelrahman· 1 shared A. M. Coyle· 1 shared A. T. Baker· 1 shared B. M. Nagalo· 1 shared C. R. Dumbauld· 1 shared

Activity by Year

2017-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. C. Roden

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Resilient CD8+ T cells maintain a high cytotoxic capacity by balancing ROS via ME1 upregulation

J. K. Gicobi, Z. Mao, G. DeFranco, Y. Li, X. Liu, J. B. Hirdler, V. V. Vianzon, E. R. Dellacecca, M. A. Hsu, W. Barham, Y. H. Kim, A. Feven, W. S. Harmsen, Y. Yan, R. S. Dronca, , H. Dong

This paper identifies CX3CR1+ CD8+ T cells with low mitochondrial membrane potential as functionally resilient, showing high cytotoxicity and reduced ROS through ME1 upregulation, which enhances their anti-tumor activity.

bioRxiv · Nov 25, 2022 · PreprintImmunology

Effects of tumor mutation burden on the antigen presentation pathway

E. M. Garcia-Rivera, J. Park, A. Desai, R. Boidot, S. Chevrier, C. Truntzer, F. Ghiringhelli, M. Borad, A. S. Mansfield

The paper examines how tumor mutation burden affects antigen presentation pathway genes and finds that APG mutations are linked to improved progression-free survival with PD-1 inhibitors.

bioRxiv · Apr 14, 2021 · PreprintImmunology

Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers

M. Arora, J. M. Bogenberger, A. M. Abdelrahman, J. Yonkus, R. Alva-Ruiz, J. L. Leiting, X. Chen, P. L. Serrano Uson, C. R. Dumbauld, A. T. Baker, S. I. Gamb, J. B. Egan, Y. Zhou, B. M. Nagalo, N. Meurice, , M. J. Borad

This study shows that combining gemcitabine/cisplatin with CDK4/6 inhibitors improves efficacy and reduces toxicity in biliary tract cancers through mechanisms involving autophagy and RRM1 reduction.

bioRxiv · Oct 26, 2020Cancer Biology

DARPP-32 and t-DARPP promote lung cancer growth through IKKα-dependent cell migration and Akt/Erk-mediated cell survival

S. K. Alam, M. Astone, P. Liu, S. R. Hall, A. M. Coyle, E. N. Dankert, D. K. Hoffman, W. Zhang, R. Kuang, A. C. Roden, A. S. Mansfield, L. H. Hoeppner

The paper shows that DARPP-32 and t-DARPP promote lung cancer growth via IKKα-dependent migration and Akt/Erk-mediated survival, with t-DARPP linked to poor survival and higher tumor stages.

bioRxiv · Dec 6, 2017Cancer Biology